SmartTRAK experts across orthopedics, sports medicine, spine and enabling technology attended this year’s 2024 Canaccord Genuity Musculoskeletal and American Academy of Orthopedic Surgeons (AAOS) annual conferences. Held from February 12-15 in San Francisco, CA, these gatherings brought together the top minds in the industry. In this post, we share some key insights and updates gleaned from these conferences, offering a glimpse into the latest trends and innovations shaping the future of orthopedic and musculoskeletal care.

• MARKET

Maxx Orthopedics*
SmartTRAK learned at AAOS 2024 that Maxx Medical is going on the offensive to grow its joint replacement business in the US and that the Company plans to launch new hip and knee products in 2024.

Paragon 28*
At AAOS 2024, Paragon 28 noted that its supply chain issues have resolved and does not expect a headwind this year. As a result, Needham believes the company can return to ~20% revenue growth in 2024.

restor3d*
Restor3d reported it currently has 157 active distribution partners calling on ~22,965 orthopedic surgeons and ~18,000 podiatrists. Management noted surgeons will bring difficult cases and from there restor3d can create additional sales opportunities. CG 2024 Musculoskeletal Conference

• REVENUES

BONESUPPORT*
BONESUPPORT highlighted the continued strength of Cerament G in North America with approximate revenues of $17.0MM in Q323 since launching in June 2023. CG 2024 Musculoskeletal Conference

OrthAlign*
At AAOS 2024, SmartTRAK learned that OrthAlign’s 2023 revenue was up +25% to $51MM, led by strong adoption of its Lantern next-generation handheld navigation system and increasing use of the Balance gap balancing feature on Lantern Knee. The company noted +37% growth in the ASC setting.

In a joint interview with Eugene Malinskiy, founder and CEO of Lazurite, and orthopedic surgeon Dr James Voos, we discuss the world’s first wireless surgical camera, the Lazurite ArthroFree camera.

Eugene Malinskiy, the founder and CEO of Lazurite, and orthopedic surgeon Dr. James Voos discuss the technological and clinical benefits of the new ArthroFree camera, the world’s first fully wireless surgical camera, with Andy Knapik, SmartTRAK's Senior Analyst, Soft Tissue & Arthroscopic Technologies.

To learn more about Lazurite and the ArthroFree System, click the following video to watch the interview (27:05 min).  For more details, interview topics by timecode are provided below. To download a complete transcript of the interview, click here.

Interview Topics By Timecode

1:25 Background of Lazurite and the ArthroFree camera.

7:05 Surgeon impressions of the ArthroFree camera.

10:10 Camera integration, image quality, battery life, ergonomics.

16:05 How the camera connects to the monitor and image capture.

19:22 How do facilities react to purchasing the ArthroFree.

22:05 Uses of the ArthroFree camera.

To download the complete transcript of the interview with Eugene Malinskiy, the founder and CEO of Lazurite, and orthopedic surgeon Dr. James Voos, just click the button below.

Soft Tissue Fixation Rebounds in Q123 To Start the Year In a Positive Direction

In Q1, the STF market experienced notable growth, primarily driven by several factors, including an increase in elective procedures, a decrease in the effects of supply chain issues and increased growth over a sluggish Q122. Overall, these factors collectively propelled the STF market to exhibit robust growth during the first quarter.

Among the many topics covered in detail inSmartTRAK's comprehensiveQ123 Soft Tissue Fixation Market Recap* are:

• Complete Q123 Soft Tissue Fixation Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All STF Companies' News, Revenues, Data, Charts and Market Shares
• Headwinds and Tailwinds
• Top Competitor Results & Highlights
• Q123 Clinical/Regulatory Highlights

In the first quarter of 2023, the orthopedic ambulatory surgical center (ASC) market in the US experienced positive developments. The market witnessed significant growth in personnel, contracts and portfolio expansion within Sports Medicine companies. In their Q1 earnings call, Zimmer Biomet* COO Ivan Tornos commented that ...

Soft Tissue Fixation Takes A Hit In Q421

After two quarters of significant growth, Soft Tissue Fixation took a hit in Q421, with another spike in COVID cases negatively affecting procedure volumes. 2021 was a year full of ups and downs due mainly to the COVID pandemic and Q4 was no different. COVID once again brought a new wave of cases, with the Omicron variant taking its toll on Soft Tissue Fixation case volumes resulting in modest YoY revenue declines over 2020.

Among the many topics covered in detail in our comprehensive Q421 Soft Tissue Fixation Market Recap* are:

Soft Tissue Fixation Continues to Pick Up Steam in Q2 2021

With the world trying to move past the negative impacts of COVID-19, the Soft Tissue Fixation market continued to make significant advancements in the second quarter of 2021. The quarter saw a continued rise in case volumes for elective sports medicine procedures worldwide driven primarily through market recovery in the wake of the COVID-19 pandemic. 

Among the many topics covered in detail in our comprehensive Q221 Soft Tissue Fixation Market Recap* are: